Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.

J Hematol Oncol · 2017 · PMC5500972 · PMID 28683766

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

At the final analysis for OS, after a median follow-up of ~20 months, ixazomib-Rd resulted in a highly significant improvement in OS versus placebo-Rd in Chinese patients with RRMM.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.